Ropes & Gray advised IDRx on the deal. Clinical stage precision cancer biopharmaceutical company IDRx announced licensing transactions with Germany-based Merck KGaA and Blueprint Medicines to...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here